Arbutus Reports Q4 and Year-End 2025 Financial Results, $2.25B Moderna Settlement, and Clinical Trials Progress

Arbutus Biopharma reported Q4 and year-end 2025 financial results, with a strong cash position of $91.5M and a $2.25B settlement with Moderna for LNP delivery technology infringement. Two additional patients from Phase 2a clinical trials of imdusiran achieved a functional cure for chronic hepatitis B. A milestone payment was received under the Alnylam LNP license for an HCC treatment product candidate. The company remains focused on maximizing its cash runway and progressing its cHBV programs.